Jason Broderick

Thomas Hutson, DO, PharmD, FACP has updated reported efficacy results from the phase 2 CLEAR study.

Androgen-deprivation therapy with the addition of apalutamide was effective when used in patients with high-risk biochemically relapsed prostate cancer.

Atezolizumab given post-resection did not improve patients’ with renal cell carcinoma, at increased risk for recurrence, clinical outcomes compared to placebo.

Potential biomarkers of overall survival outcomes have been identified in an exploratory post-hoc analysis of the phase 3 TITAN trial.

Neoadjuvant axitnib demonstrated significant reductions in tumor size and complexity, allowing for partial nephrectomy in a subgroup of patients with renal cell carcinoma.

NeoAvAx trial results show that neoadjuvant avelumab/axitinib may be beneficial to patients with renal cell carcinoma.

Based on pooled long-term data, the safety of darolutamide is solidified in patients with metastatic castration resistant prostate cancer.

A phenomenon known as the “obesity paradox,” has been reported in prostate cancer as well as other genitourinary malignancies.

According to updated data from the phase 1b COSMIC-021 trial, treatment with cabozantinib and atezolizumab continued to demonstrate clinically meaningful activity in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, including those with high-risk clinical features.

Alan Lombard, PhD, shared insight on mechanisms of resistance to PARP inhibition with olaparib and explained how this resistance may be overcome.

In patients with progressive prostate-specific membrane antigen positive metastatic castration-resistant prostate cancer receiving treatment in the phase 3 VISION trial, the addition of the targeted radioligand therapy 177Lu-PSMA-617 to standard of care led to a nearly 40% reduction in the risk of death versus SOC alone.

A significant increase in the risk of disease recurrence among patients with high level of the nicotine metabolite, urinary cotinine, who had non–muscle invasive bladder cancer and were smokers.

In patients with muscle-invasive bladder cancer combining transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise as a bladder-sparing treatment strategy.

Data from the phase 2 the phase 3 SWOG S1216 presented during the ASCO Annual Meeting shows numerical overall survival improvement with he experimental combination that missed the threshold for statistical significance.

In the phase 3 ACIS study, the addition of apalutamide to abiraterone acetate lead to a reduction in the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.

Treatment with mitomycin-containing reverse thermal gel, led to complete responses in over 50% of patients with low-grade upper tract urothelial carcinoma, which were maintained at 1 year, final results from the pivotal phase 3 OLYMPUS trial show.

Treatment with MK-6482, an investigational HIF2α inhibitor, demonstrated durable efficacy as treatment of patients with Von Hippel-Lindau-associated renal cell carcinoma and non-renal lesions, according to phase 2 data presented during the 21st Annual Meeting of the Society of Urologic Oncology.

In a subgroup of patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer, the novel intravesical gene-mediated therapy nadofaragene firadenovec maintained its efficacy, according to a poster shared during the 21st Annual Meeting of the Society of Urologic Oncology.

Phase 3 BGB-A317-307 trial results showed statistically significant improvements in progression-free survival with tislelizumab plus chemotherapy versus chemotherapy alone in Chinese patients with untreated advanced squamous non–small cell lung cancer.

“Preliminary data for the 18 patients who have received belantamab mafodotin 2.5 mg/kg single dosing with bortezomib/dexamethasone suggests that this combination has an acceptable safety profile with no new safety signals identified."

"Avelumab first-line maintenance in patients whose disease has not progressed with platinum-based induction therapy is a new first-line standard of care for advanced urothelial carcinoma."

Phase Ib results presented at the 2017 ASH Annual Meeting demonstrated that zanubrutinib (BGB-3111), an investigational BTK inhibitor, had encouraging rates of clinical activity in patients with non-Hodgkin lymphoma, including an overall response rate of 78% among patients with marginal zone lymphoma.

Gefitinib (Iressa) was recently approved by the FDA for the frontline treatment of patients who have metastatic, EGFR-positive non-small cell lung cancer (NSCLC) with an exon 19 deletion or exon 21 (L858R) substitution.

Venetoclax (GDC-0199/ABT-199), a Bcl-2 inhibitor, has been granted a breakthrough therapy designation by the FDA for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The designation is specific to those patients who harbor a 17p deletion (del[17p]).